• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西太平洋区域绿灯委员会:进展与未来方向

Western Pacific Regional Green Light Committee: progress and way forward.

作者信息

Islam T, Marais B J, Nhung N V, Chiang C-Y, Yew W W, Yoshiyama T, Mira N R, van den Broek J, Lumb R, Nishikiori N, Reichman L B

机构信息

Stop TB and Leprosy Elimination, Division of Communicable Diseases, World Health Organization, Western Pacific Regional Office, Manila, Philippines.

Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, Australia.

出版信息

Int J Infect Dis. 2015 Mar;32:161-5. doi: 10.1016/j.ijid.2015.01.001.

DOI:10.1016/j.ijid.2015.01.001
PMID:25809774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5384424/
Abstract

The Western Pacific Regional Green Light Committee (rGLC WPR) was established in 2011 to promote the rational scale-up of programmatic management of drug-resistant tuberculosis (PMDT). We reflect on its achievements, consider the challenges faced, and explore its potential future role. Achievements include the supervision and support of national PMDT action plans, increased local ownership, contextualized guidance, and a strong focus on regional capacity building, as well as a greater awareness of regional challenges. Future rGLC activities should include (1) advocacy for high-level political commitment; (2) monitoring, evaluation, and supervision; (3) technical support and contextualized guidance; and (4) training, capacity building, and operational research. Regional activities require close collaboration with both national and global efforts, and should be an important component of the new Global Drug-resistant TB Initiative.

摘要

西太平洋区域绿灯委员会(rGLC WPR)成立于2011年,旨在推动耐药结核病规划管理(PMDT)的合理扩大规模。我们反思其成就,考虑所面临的挑战,并探索其未来可能发挥的作用。成就包括对国家PMDT行动计划的监督和支持、增强地方自主权、因地制宜的指导、高度重视区域能力建设以及对区域挑战有了更强的认识。rGLC未来的活动应包括:(1)倡导高层政治承诺;(2)监测、评估和监督;(3)技术支持和因地制宜的指导;(4)培训、能力建设和行动研究。区域活动需要与国家和全球的努力密切协作,并且应成为新的全球耐药结核病倡议的重要组成部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92fc/5384424/2f92b62e728a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92fc/5384424/d5a0b46c6766/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92fc/5384424/2f92b62e728a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92fc/5384424/d5a0b46c6766/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92fc/5384424/2f92b62e728a/gr2.jpg

相似文献

1
Western Pacific Regional Green Light Committee: progress and way forward.西太平洋区域绿灯委员会:进展与未来方向
Int J Infect Dis. 2015 Mar;32:161-5. doi: 10.1016/j.ijid.2015.01.001.
2
Progress in programmatic management of drug-resistant TB, WHO Eastern Mediterranean Region, 2018-2023.2018 - 2023年,世界卫生组织东地中海区域耐多药结核病规划管理进展
IJTLD Open. 2024 Sep 1;1(9):398-403. doi: 10.5588/ijtldopen.24.0348. eCollection 2024 Sep.
3
Global scale-up of the programmatic management of multidrug-resistant tuberculosis.耐多药结核病规划管理在全球范围内的推广。
Indian J Tuberc. 2014 Apr;61(2):108-15.
4
Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.越南耐多药结核病患者的检测与治疗挑战。
BMC Public Health. 2015 Sep 29;15:980. doi: 10.1186/s12889-015-2338-5.
5
Tuberculosis结核病
6
A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT).耐药结核病规划管理下多药耐药结核病(MDR-TB)长疗程与短疗程的综合综述
Cureus. 2024 Jan 22;16(1):e52706. doi: 10.7759/cureus.52706. eCollection 2024 Jan.
7
Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.西太平洋地区抗击结核病流行:现状与未来挑战
Kekkaku. 2010 Jan;85(1):9-16.
8
Evaluation of the 2016-2020 regional tuberculosis response framework, WHO Western Pacific Region.评估 2016-2020 年世界卫生组织西太平洋区域区域结核病应对框架。
Bull World Health Organ. 2021 May 1;99(5):330-341A. doi: 10.2471/BLT.20.268060. Epub 2021 Mar 2.
9
Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.耐多药结核病的规划管理:更新后的研究议程
PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016.
10
Collaboration for implementation of decentralisation policy of multi drug-resistant tuberculosis services in Zambia.在赞比亚合作实施耐多药结核病服务权力下放政策。
Health Res Policy Syst. 2024 Aug 19;22(1):112. doi: 10.1186/s12961-024-01194-8.

引用本文的文献

1
Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region.世界卫生组织西太平洋区域六个优先国家符合世卫组织建议的耐药结核病防治进展。
Western Pac Surveill Response J. 2022 Dec 19;13(4):1-12. doi: 10.5365/wpsar.2022.13.4.972. eCollection 2022 Oct-Dec.
2
Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam.越南耐多药结核病治疗患者的管理与治疗结果。
Public Health Action. 2016 Mar 21;6(1):25-31. doi: 10.5588/pha.15.0068. Epub 2016 Feb 11.

本文引用的文献

1
Market size and sales pattern of tuberculosis drugs in the Philippines.菲律宾结核病药物的市场规模与销售模式。
Public Health Action. 2013 Dec 21;3(4):337-41. doi: 10.5588/pha.13.0094.
2
Drug-resistant tuberculosis in the WHO Western Pacific Region.世界卫生组织西太平洋区域的耐多药结核病
Western Pac Surveill Response J. 2014 Dec 18;5(4):34-46. doi: 10.5365/WPSAR.2014.5.4.007. eCollection 2014 Oct-Dec.
3
A poor drug-resistant tuberculosis programme is worse than no programme: time for a change.一个糟糕的耐多药结核病防治项目比没有项目更糟糕:是时候做出改变了。
Int J Tuberc Lung Dis. 2013 Jun;17(6):714-8. doi: 10.5588/ijtld.12.0989. Epub 2013 Apr 9.
4
The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity?
Int J Tuberc Lung Dis. 2012;16(3):285-6. doi: 10.5588/ijtld.12.0066.
5
Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme.应对耐多药结核病危机:将规划管理纳入菲律宾国家结核病规划的主流。
Int J Tuberc Lung Dis. 2010 Jun;14(6):751-7.
6
DOTS and DOTS-Plus: what's in a name.
Int J Tuberc Lung Dis. 2000 Nov;4(11):995-6.